...
首页> 外文期刊>Journal of hypertension >Platelet alpha2-adrenoceptor alterations in patients with essential hypertension are normalized after treatment with doxazosin but not propranolol.
【24h】

Platelet alpha2-adrenoceptor alterations in patients with essential hypertension are normalized after treatment with doxazosin but not propranolol.

机译:原发性高血压患者的血小板α2-肾上腺素受体改变在用多沙唑嗪而非普萘洛尔治疗后可正常化。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVE: Marked alterations have been demonstrated to occur in the platelet alpha2-adrenoceptors of patients with essential hypertension. The purpose of this study was to determine whether antihypertensive treatment with alpha-adrenergic blocker doxazosin or beta-adrenergic blocker propranolol can affect the affinity and the density of platelet alpha2-adrenoceptors in such patients. SUBJECTS AND METHODS: In two groups of 22 previously untreated, essential hypertensive patients, the mean affinity (Kd) and density (B(max)) of platelet alpha2-adrenoceptors were studied by [3H]-UK 14304 binding assays; the first assays were performed before any medication was begun, the second were performed after treatment for up to 13 weeks with doxazosin or propranolol. A third group of 22 healthy normotensive volunteers matched by age, sex and body mass index was used as control. RESULTS: Blood pressure did not differ significantly in the two hypertensive groups, and treatment with the two drugs resulted in closely similar, normal blood pressure levels. Kd and B(max) values were significantly higher in the two hypertensive groups than in controls. After treatment with propranolol the binding parameters did not change significantly, whereas after treatment with doxazosin Kd and B(max) returned to normotensive values. CONCLUSIONS: In previously untreated, essential hypertensive patients platelet alpha2-adrenoceptors have a lower affinity but a higher density than in normotensive subjects. Despite similar effects on blood pressure, the treatment with the alpha-adrenergic blocker doxazosin is followed by restoration of normal findings in the binding assays of platelet alpha2-adrenoceptors whereas the treatment with the beta-adrenergic blocker propranolol does not alter the Kd and B(max) values.
机译:目的:已证明明显的改变发生在原发性高血压患者的血小板α2-肾上腺素受体中。这项研究的目的是确定用α-肾上腺素能阻断剂多沙唑嗪或β-肾上腺素能阻断剂普萘洛尔进行降压治疗是否可以影响此类患者中血小板α2肾上腺素受体的亲和力和密度。研究对象和方法:在22名先前未接受治疗的原发性高血压患者的两组中,通过[3H] -UK 14304结合试验研究了血小板α2-肾上腺素受体的平均亲和力(Kd)和密度(B(max))。第一种测定在开始任何药物治疗之前进行,第二种测定在用多沙唑嗪或普萘洛尔治疗长达13周后进行。第三组由年龄,性别和体重指数匹配的22名健康血压正常志愿者作为对照。结果:两个高血压组的血压没有显着差异,并且两种药物的治疗导致了相似的正常血压水平。两个高血压组的Kd和B(max)值均显着高于对照组。用心得安治疗后,结合参数没有明显改变,而用多沙唑嗪治疗后的Kd和B(max)恢复至正常血压值。结论:在原先未经治疗的原发性高血压患者中,血小板α2-肾上腺素受体的亲和力较正常人低,但密度较高。尽管对血压有类似的影响,但用α-肾上腺素能阻断剂多沙唑嗪治疗后,血小板α2-肾上腺素能受体的结合试验中恢复了正常的发现,而用β-肾上腺素能阻断剂普萘洛尔治疗不会改变Kd和B(最大)值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号